|
| Press Releases |
|
 |
|
| Tuesday, August 6, 2024 |
|
|
Eisai: Update Regarding the Regulatory Status of LEQEMBI Subcutaneous Formulation |
| Eisai Co., Ltd. reconfirmed that the regulatory status for anti-amyloid beta (Aβ) protofibril antibody LEQEMBI (generic name:lecanemab) subcutaneous (SC) autoinjector, explained at the Financial Disclosure Meeting on August 2, 2024, is as follows. more info >> |
|
| Wednesday, July 31, 2024 |
|
|
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at AAIC 2024 |
| Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI), an anti-amyloid beta (Abeta) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 2024, held in Philadelphia, and virtually. more info >> |
|
| Monday, July 29, 2024 |
|
|
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Approval (MAA) for the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab as treatment for early AD (mild cognitive impairment due to Alzheimer?s disease (AD) and mild AD). more info >> |
|
| Thursday, July 25, 2024 |
|
|
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration |
| Eisai Co., Ltd. and EcoNaviSta Inc. announced today that they have entered into a business alliance agreement and commenced collaboration with the aim of building an ecosystem in the area of dementia, which is a pressing matter in Japan's super-aging society. more info >> |
|
| Tuesday, July 23, 2024 |
|
|
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024 |
| The conference will be held in Philadelphia and virtually from July 28 to August 1, 2024. Eisai will present data and research in four (4) oral and 15 poster presentations at the meeting and will host two (2) sessions on lecanemab. more info >> |
|
| Friday, July 12, 2024 |
|
|
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel |
| Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab) has been approved in Israel as a treatment of Alzheimer's disease (AD). more info >> |
|
| Thursday, July 11, 2024 |
|
|
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (brand name in Hong Kong: generic name: lecanemab) for treatment of Alzheimer's disease (AD). more info >> |
|
| Tuesday, July 2, 2024 |
|
|
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) |
| Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug conjugate (ADC) due to ongoing portfolio prioritization efforts within Bristol Myers Squibb. more info >> |
|
| Friday, June 28, 2024 |
|
|
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China |
| China is the third country to launch LEQEMBI following the United States and Japan. more info >> |
|
| Friday, June 21, 2024 |
|
|
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City |
| Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo City, Tokyo, which the company has been commissioned to conduct in order to raise awareness of dementia and promote early detection, and will continue the commission for this project in FY2024. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
WiseChain.io Unveils AI-Powered Social Trading and Tailored Investment Solutions for Canadians and Seniors
Mar 29, 2025 11:00 HKT/SGT
|
|
|
Mobvoi 2024 Annual Results Announcement 
Mar 29, 2025 02:19 HKT/SGT
|
|
|
Dynasty's Profit Attributable to Owners of The Company Increases by 57%
Mar 29, 2025 00:42 HKT/SGT
|
|
|
Hua Medicine Announces 2024 Annual Results
Mar 28, 2025 21:51 HKT/SGT
|
|
|
Analogue FY2024 Revenue Rose to HK$6,450 Million with Adjusted Profit Attributable to Owners of the Company Increased to HK$206 Million
Mar 28, 2025 21:21 HKT/SGT
|
|
|
Nissin Foods Announces 2024 Annual Results
Mar 28, 2025 20:56 HKT/SGT
|
|
|
Accelerated Transformation of New Quality Productive Forces with Growing Efficacy in Sci-Tech Innovation Layout
Mar 28, 2025 18:21 HKT/SGT
|
|
|
WL Delicious Announced 2024 Annual Results
Mar 28, 2025 16:55 HKT/SGT
|
|
|
Leading the Future with Reform and Innovation, Embarking on a New Chapter of Global Development
Mar 28, 2025 16:05 HKT/SGT
|
|
|
Mitsubishi Corporation, ADM Sign Non-Binding MOU, Form Strategic Alliance
Mar 28, 2025 16:29 JST
|
|
|
CIMC Group Announces 2024 Annual Results
Mar 28, 2025 14:32 HKT/SGT
|
|
|
Tingyi (Cayman Islands) Holding Corp. 'Dual-wheel Drive of Product Structure & Operational Efficiency' to Enhance Profitability in 2024 with GPM Improving to 33.1% and EBITDA Rising 17.3%
Mar 28, 2025 13:58 HKT/SGT
|
|
|
Sonimedi Captivates the European Beauty Market - Wins 'Best Hair Product' Award at Cosmoprof Bologna 2025
Mar 28, 2025 13:46 HKT/SGT
|
|
|
Everbright Grand China Assets Recorded Revenue of RMB 45.9 Million in 2024
Mar 28, 2025 13:27 HKT/SGT
|
|
|
Dubai AI Festival returns for highly anticipated second edition as part of the inaugural Dubai AI Week
Mar 28, 2025 12:35 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
